改进人用药物的监管环境风险评估:新立法中所需的变化
Daniela Gildemeister1, Caroline T A Moermond2, Cecilia Berg3
1German Environment Agency (Umweltbundesamt), Wörlitzer Platz 1, D-06844, Dessau-Roßlau, Germany.
本研究提出立法变更,以加强药品的环境风险评估 (ERA),确保环境保护,而不会影响患者获得药物的机会. 关键建议包括强制性ERA和改进数据透明度.
科学领域:
- 环境科学 环境科学
- 药理学 药理学是指药理学的学科.
- 监管事务 监管事务
背景情况:
- 制药的使用给环境带来了挑战.
- 目前对药品的环境风险评估 (ERA) 需要加强.
- 修订制药立法是必要的,以应对环境风险.
研究的目的:
- 要总结关于人用药品的ERA的当前状态.
- 建议立法变更,以改善环境保护.
- 确保药品的可用性不受环境风险管理的影响.
主要方法:
- 专家评估了人用药品当前的ERA.
- 定义和讨论了改善ERA的六个监管目标.
- 立法提案是基于专家分析而制定的.
主要成果:
- 建议在营销许可证 (MA) 时强制执行ERA.
- 建议执行风险减轻措施,并重新评估ERA.
- 建议促进数据交换,基于物质的评估,数据透明度以及现有API的追赶程序.
结论:
- 立法变化对于协调对环境风险的评估至关重要.
- 环境风险的有效管理需要更新的监管框架.
- 拟议的变化旨在平衡环境保护与制药的可用性.
更多相关视频
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
05:46Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
Published on: August 1, 2018
相关概念视频
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
